Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2a, Open-Label, First-In-Human, Two-Part, Single And Multiple Ascending Dose Study To Evaluate The Safety, Tolerability, And Efficacy Of VMB-100 In Female Subjects With Moderate Stress Urinary Incontinence

Next Previous
Trial Profile

A Phase 2a, Open-Label, First-In-Human, Two-Part, Single And Multiple Ascending Dose Study To Evaluate The Safety, Tolerability, And Efficacy Of VMB-100 In Female Subjects With Moderate Stress Urinary Incontinence

Status: Not yet recruiting
Phase of Trial: Phase II

Latest Information Update: 04 Apr 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs VMB-100 (Primary)
  • Indications Urinary incontinence
  • Focus Adverse reactions; First in man; Proof of concept
  • Sponsors Versameb AG

Most Recent Events

  • 01 Apr 2025 Planned End Date changed from 1 Nov 2028 to 1 Apr 2029.
  • 01 Apr 2025 Planned primary completion date changed from 1 Jun 2027 to 1 Nov 2027.
  • 01 Apr 2025 Planned initiation date changed from 1 Apr 2025 to 1 Sep 2025.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top